MedTrace Logo

Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously

NCT00635414 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-01-25

No results posted yet for this study

Summary

This study looks at the effect on basal and pentagastrin-stimulated acid output of 40 mg Esomeprazole (Nexium) administered orally and intravenously as a 15-minute infusion to people with symptoms of Gastroesophageal Reflux Disease (GERD)

Conditions

  • GERD

Interventions

DRUG

Esomeprazole

40mg oral

DRUG

Esomeprazole

15 minute intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Paula Fernstrom · Nexium Global Product Director, AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2002-10-31
Completion
2002-10-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00635414 on ClinicalTrials.gov